Clinical significance of PEA3 in human breast cancer

Surgery. 2002 Jan;131(1 Suppl):S222-5. doi: 10.1067/msy.2002.119792.


Background: Recently, PEA3 has been reported to suppress HER-2/neu overexpression by promoter activity and thereby inhibit tumorigenesis of breast cancer both in vitro and in vivo.

Methods: The expression of PEA3 and the clinicopathologic features of 89 patients with breast cancer were investigated. The expression of PEA3 was immunohistochemically detected in 42 (47.2%) of 89 patients.

Results: The correlation between the expression of PEA3 and the clinicopathologic features were nil with regard to lymph node metastasis, hormone receptor, blood vessel invasion, and lymphatic vessel invasion. The disease-free survival rate was shorter for the PEA3-negative groups than for the PEA3-positive ones, but with no statistically significant difference. The overall survival rate after surgical resection in patients who were PEA3-positive vs PEA3-negative was 100% vs 87.2%, respectively, at 3 years and 89.8% vs 72.7%, respectively, at 6 years (P =.0472).

Conclusions: The expression of PEA3 in breast cancer might therefore be a novel prognostic factor.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology*
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Survival Rate
  • Transcription Factors / analysis*


  • Transcription Factors
  • transcription factor PEA3